Nanocrystal-loaded dissolving microneedles: A novel transdermal strategy for long-acting tizanidine administration
Source abstract
Abstract
Spasticity is commonly managed with tizanidine (TZN), a centrally acting α 2 -adrenergic agonist. However, its clinical application is limited by poor oral bioavailability and a short elimination half-life, necessitating frequent dosing and thereby reducing patient adherence. In this study, a trilayer dissolving microneedle array patch (MAP) incorporating TZN was developed as an alternative minimally invasive platform for long-acting transdermal delivery. TZN nanocrystals (NCs) with a mean particle size of 243 ± 21 nm and a polydispersity index (PDI) < 0.2 were successfully prepared, resulting in supersaturated solubility and an increased dissolution rate. Ex vivo permeation studies demonstrated that MAP-mediated skin penetration is essential for transdermal delivery and that NC-loaded formulations provide markedly enhanced delivery efficiency. Importantly, the in vivo pharmacokinetic evaluation in Sprague-Dawley® rats demonstrated that MAPs incorporated with NCs (C max = 229.23 ± 72.34 ng/mL, mean retention time (MRT) (52.46 ± 13.72 h)) achieved markedly improved systemic exposure (7682.36 ± 1784.77 ng/mL∗h) compared with coarse drug-loaded MAPs (AUC 0–28 days = 4936.06 ± 882.51 ng/mL∗h, p < 0.05) and intramuscular (IM) injection (AUC 0–28 days = 795.99 ± 146.94 ng/mL∗h, p < 0.05). These findings suggest that the integration of TZN NCs into dissolving MAPs represents a novel and effective transdermal strategy for the sustained systemic delivery of TZN. In addition to improving patient adherence and therapeutic outcomes in spasticity management, this platform offers a generalisable approach for enhancing the transdermal delivery of poorly soluble drugs and may inform the future design of long-acting delivery for other compounds.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (76)
Show source-provided references
1. Spasticity: a general outlook of pathogenesis and current management10.30574/ijsra.2024.13.1.1681 ↗
2. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders10.2165/00003495-199753030-00007 ↗
3. Tizanidine: advances in pharmacology & therapeutics and drug formulations10.2147/JPR.S461032 ↗
4. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects10.1016/j.clinthera.2008.12.014 ↗
5. Microneedle-mediated transdermal delivery of tizanidine hydrochloride10.1007/978-1-4939-9798-5_13 ↗
6. Donnelly · 2012
7. Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms10.1016/j.ejps.2021.105920 ↗
8. Transdermal films containing tizanidine: in vitro and in vivo evaluation10.1016/S1773-2247(14)50013-5 ↗
9. A combined approach of chemical enhancers and sonophoresis for the transdermal delivery of tizanidine hydrochloride10.1080/10717540802605053 ↗
10. Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation10.1080/08982104.2019.1684940 ↗
11. Microneedles for oral mucosal delivery–current trends and perspective on future directions10.1080/17425247.2023.2264189 ↗
12. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development10.1016/j.mser.2016.03.001 ↗
13. Donnelly · 2015
14. Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs10.1016/j.jconrel.2014.02.007 ↗
15. Intramuscular injection technique: an evidence-based approach10.7748/ns.29.4.52.e9183 ↗
16. Microneedles: a smart approach and increasing potential for transdermal drug delivery system10.1016/j.biopha.2018.10.078 ↗
17. Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs10.1002/adfm.202005792 ↗
18. Enhanced long-acting simvastatin delivery via effervescent powder-carrying hollow microneedles and nanocrystal-loaded microneedles10.1016/j.ijpharm.2024.124691 ↗
19. Designing microneedles for intravaginal delivery: current challenges and prospects10.1007/978-981-96-3916-8_2 ↗
20. Overcoming poor aqueous solubility of drugs for oral delivery
21. The rate of solution of solid substances in their own solutions10.1021/ja02086a003 ↗
22. Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation10.3109/03639045.2016.1173051 ↗
23. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat10.1016/j.ijpharm.2007.02.030 ↗
24. Dissolving microarray patches for transdermal delivery of risperidone for schizophrenia management10.1016/j.ijpharm.2024.124342 ↗
25. Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs10.1002/adfm.202005792 ↗
26. Calcipotriol nanosuspension-loaded trilayer dissolving microneedle patches for the treatment of psoriasis: in vitro delivery and in vivo antipsoriatic activity studies10.1021/acs.molpharmaceut.3c01223 ↗
27. Overview of milling techniques for improving the solubility of poorly water-soluble drugs
28. Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride10.1016/j.ijpharm.2021.120885 ↗
29. Polymeric microarray patches for enhanced transdermal delivery of the poorly soluble drug olanzapine10.1021/acsami.3c05553 ↗
30. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis10.1016/j.ejpb.2020.06.025 ↗
31. Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis10.1016/j.matdes.2022.111416 ↗
32. A proposed model membrane and test method for microneedle insertion studies10.1016/j.ijpharm.2014.05.042 ↗
33. Solubility and fractionation of polyvinylpyrrolidone10.1002/pol.1952.120080508 ↗
34. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms10.1002/jps.2600561005 ↗
35. 2005
36. Validation of analytical procedures–ICH Q2 (R2)
37. Q2 (R1) validation of analytical procedures: text and methodology10.1002/9781118971147.ch5 ↗
38. Guideline · 2022
39. Validity of particle size analysis techniques for measurement of attrition of needle-shaped particles that occurs during vacuum agitated powder drying10.1039/C1AN15836H ↗
40. Dissolving microarray patches loaded with a rotigotine nanosuspension: a potential alternative to Neupro® patch10.1016/j.jconrel.2024.06.039 ↗
41. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods10.1111/j.2042-7158.2010.01022.x ↗
42. Steric stabilization of nanoparticles: size and surface properties10.1016/0378-5173(96)04486-9 ↗
43. Origin of stabilisation of aqueous foams in nanoparticle–surfactant mixtures10.1039/b811291f ↗
44. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems10.3390/pharmaceutics10020057 ↗
45. Controlled freezing and freeze drying: a versatile route for porous and micro‐/nano‐structured materials10.1002/jctb.2495 ↗
46. Physicochemical characteristics and antibacterial activities of freeze-thawed polyvinyl alcohol/andrographolide hydrogels10.1021/acsomega.2c05110 ↗
47. The measurement of the crystallinity of polymers by DSC10.1016/S0032-3861(02)00235-5 ↗
48. Structural and thermal studies of PVA: NH4I10.1016/j.jpcs.2009.06.005 ↗
49. Differential scanning calorimetry techniques: applications in biology and nanoscience
50. Thermal behavior of poly (vinyl alcohol) in the form of physically crosslinked film10.3390/polym15081843 ↗
51. The theory of ostwald ripening10.1007/BF01017860 ↗
52. Thermal degradation of olive solid waste: influence of particle size and oxygen concentration10.1016/j.resconrec.2009.04.010 ↗
53. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?10.1002/jps.21650 ↗
54. The effect of the particle size reduction on the biorelevant solubility and dissolution of poorly soluble drugs with different acid-base character10.3390/pharmaceutics15010278 ↗
55. Efficient drug delivery into skin using a biphasic dissolvable microneedle patch with water‐insoluble backing10.1002/adfm.202103359 ↗
56. A review on PLA-Based biodegradable materials for biomedical applications10.1016/j.giant.2024.100261 ↗
57. Trilayer microneedle array assisted transdermal and intradermal delivery of dexamethasone10.1016/j.ijpharm.2021.121295 ↗
58. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution10.1016/j.jconrel.2010.08.008 ↗
59. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique10.1007/s11095-010-0169-8 ↗
60. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension10.1016/j.jconrel.2018.11.002 ↗
61. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays10.1016/j.ijpharm.2012.05.069 ↗
62. Microneedle-mediated transdermal delivery of biopharmaceuticals10.3390/pharmaceutics15010277 ↗
63. Microneedle mediated transdermal delivery of protein, peptide and antibody based therapeutics: current status and future considerations10.1007/s11095-020-02844-6 ↗
64. Hydrogel-forming microarray patches with solid dispersion reservoirs for transdermal long-acting microdepot delivery of a hydrophobic drug10.1016/j.jconrel.2023.03.003 ↗
65. Novel bilayer microarray patch‐assisted long‐acting micro‐depot cabotegravir intradermal delivery for HIV pre‐exposure prophylaxis
66. Fabrication of tizanidine loaded patches using flaxseed oil and coriander oil as a penetration enhancer for transdermal delivery10.3390/polym13234217 ↗
67. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients10.1111/j.1742-1241.2007.01660.x ↗
68. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud)10.1136/jnnp.57.11.1355 ↗
69. Dissolving microneedles: applications and growing therapeutic potential10.1016/j.jconrel.2022.05.045 ↗
70. Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis10.1016/j.jconrel.2017.07.032 ↗
71. Long-acting microneedle formulations10.1016/j.addr.2023.115055 ↗
72. Nanocrystals for controlled delivery: state of the art and approved drug products10.1080/17425247.2022.2110579 ↗
73. Formulation and evaluation of tizanidine hydrochloride loaded ethosomes for transdermal delivery
74. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization10.1080/08982104.2018.1524482 ↗
75. Atorvastatin-loaded dissolving microarray patches for long-acting microdepot delivery: comparison of nanoparticle and microparticle drug formulations
76. Transdermal patches: history, development and pharmacology10.1111/bph.13059 ↗